In addition, recent data have demonstrated that afatinib plus paclitaxel may be particularly more effective than single afatinib treatment, hence, combinitaion afatinib and chemotherapy may be a better option in HER2-positive NSCLC patients [25]. Here, ERBB2 is linked to non-small cell lung carcinoma.